Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.76 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.59 |
| ▸ | CMA1 | P23946 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1771061 | 0.86 | BRD4 (1.00) | BRD4CREBBPMEN1KMT2ABRD2 | |
| SCHEMBL13090753 | 0.81 | BRD4 (0.61) | BRD4CREBBPAKR1B1BRD2TRPV1 | |
| SCHEMBL25249364 | 0.80 | CMA1 (0.60) | BRD4CREBBPCMA1AHRMEN1 | |
| SCHEMBL3604431 | 0.79 | BRD4 (0.59) | BRD4CREBBPBRD2TRPV1CRBN | |
| SCHEMBL27554931 | 0.79 | BRD4 (0.59) | BRD4CREBBPCDK5CDK5R1TRPV1 | |
| SCHEMBL3599751 | 0.79 | BRD4 (0.59) | BRD4CREBBPMEN1KMT2ABRD2 | |
| SCHEMBL4117443 | 0.79 | CMA1 (0.50) | BRD4CREBBPCMA1AHRMEN1 | |
| SCHEMBL13545265 | 0.77 | BRD4 (0.56) | BRD4CREBBPTRPV1 | |
| SCHEMBL31490089 | 0.76 | BRD4 (0.54) | BRD4CREBBPTRPV1TDP2 | |
| SCHEMBL4123663 | 0.76 | BRD4 (0.54) | BRD4CREBBPTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020139992-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-8168644-B2 | Quinazolinone derivatives as tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-01 | — | — | US | disclosed |
| US-8168644-B2 | Quinazolinone derivatives as tubulin polymerization inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-01 | — | — | US | disclosed |
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028433-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | TUBB3, TUBB1, TUBA1C | BRD4 164/4885CREBBP 2730/4885CMA1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.